{"nctId":"NCT00380081","briefTitle":"A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia","startDateStruct":{"date":"2006-04"},"conditions":["Insomnia"],"count":82,"armGroups":[{"label":"placebo/zolpidem 3.5/zolpidem 1.75","type":"EXPERIMENTAL","interventionNames":["Drug: zolpidem tartrate sublingual tablet 3.5mg","Drug: zolpidem tartrate sublingual tablet 1.75mg","Drug: Placebo"]},{"label":"placebo/zolpidem 1.75/zolpidem 3.5","type":"EXPERIMENTAL","interventionNames":["Drug: zolpidem tartrate sublingual tablet 3.5mg","Drug: zolpidem tartrate sublingual tablet 1.75mg","Drug: Placebo"]},{"label":"zolpidem 3.5/placebo/zolpidem 1.75","type":"EXPERIMENTAL","interventionNames":["Drug: zolpidem tartrate sublingual tablet 3.5mg","Drug: zolpidem tartrate sublingual tablet 1.75mg","Drug: Placebo"]},{"label":"zolpidem 3.5/zolpidem 1.75/placebo","type":"EXPERIMENTAL","interventionNames":["Drug: zolpidem tartrate sublingual tablet 3.5mg","Drug: zolpidem tartrate sublingual tablet 1.75mg","Drug: Placebo"]},{"label":"zolpidem 1.75/placebo/zolpidem 3.5","type":"EXPERIMENTAL","interventionNames":["Drug: zolpidem tartrate sublingual tablet 3.5mg","Drug: zolpidem tartrate sublingual tablet 1.75mg","Drug: Placebo"]},{"label":"zolpidem 1.75/zolpidem 3.5/placebo","type":"EXPERIMENTAL","interventionNames":["Drug: zolpidem tartrate sublingual tablet 3.5mg","Drug: zolpidem tartrate sublingual tablet 1.75mg","Drug: Placebo"]}],"interventions":[{"name":"zolpidem tartrate sublingual tablet 3.5mg","otherNames":["Intermezzo®"]},{"name":"zolpidem tartrate sublingual tablet 1.75mg","otherNames":["Intermezzo®"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Insomnia as defined by DSM-IV criteria and supported by subject diary\n* Male or female between the ages of 18-64 years\n* Body mass index (BMI) between 18-34 kg/m\\^2\n* Females of childbearing potential must use a medically acceptable method of contraception\n* Capable of understanding and willing to comply with study procedures and has provided informed consent\n\nExclusion Criteria:\n\n* Females who are pregnant, breast-feeding or have a positive pregnancy test\n* Any circadian rhythm disorder including planned travel across several time zones during the study period\n* Known hypersensitivity to Zolpidem\n* Has performed regular shift work with the past several months prior to screening\n* An acute clinically significant illness or surgery as determined by the PI within 30 days of screening\n* Patients that have used any central nervous system (CNS) medication or other medication known to impact the sleep/wake cycle\n* A history of psychiatric disorder as defined by DSM-IV\n* A history of drug addiction or alcohol abuse\n* Any current significant disease, unless adequately controlled with a protocol allowed medication\n* Known history of HIV or Hepatitis B or C\n* Patients who have received an investigational drug within several months of screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Latency to Persistent Sleep After Middle-of-the-Night Awakening as Measured by Polysomnography","description":"Polysomnography was used to measure the time to return to persistent sleep after a middle-of-the-night (MOTN) awakening for each day of every two-day treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.69","spread":null},{"groupId":"OG001","value":"16.89","spread":null},{"groupId":"OG002","value":"28.12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Responders Based on Polysomnography Latency to Persistent Sleep After Middle-of-the-Night Awakening","description":"Polysomnography was used to measure the time to return to persistent sleep after a middle-of-the-night (MOTN) awakening for each day of every two-day treatment period. A participant was considered to be a responder if the time to return to persistent sleep was less than twenty minutes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Sleep Time After Scheduled Middle-of-the-Night Awakening Measured by Polysomnography","description":"Polysomnography was used to measure the time from return to persistent sleep after a middle-of-the-night (MOTN) awakening until final awakening for each day of every two-day treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"208.99","spread":null},{"groupId":"OG001","value":"197.80","spread":null},{"groupId":"OG002","value":"183.12","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Total Sleep Time After Scheduled Middle-of-the-Night Awakening Measured by Polysomnography for Participants With More Severe Insomnia","description":"Polysomnography was used to measure the time from return to persistent sleep after a middle-of-the-night (MOTN) awakening until final awakening for each day of every two-day treatment period in the subpopulation of patients with greater than 60 minutes to fall asleep after a MOTN awakening at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"194.58","spread":null},{"groupId":"OG001","value":"179.98","spread":null},{"groupId":"OG002","value":"166.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Subjective Total Sleep Time After Scheduled Middle-of-the-Night Awakening","description":"The time from return to persistent sleep after a middle-of-the-night (MOTN) awakening until final awakening for each day of every two-day treatment period was recorded by each participant using the Treatment Morning Sleep Questionnaire.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"172.51","spread":null},{"groupId":"OG001","value":"162.36","spread":null},{"groupId":"OG002","value":"148.61","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Latency to Persistent Sleep After Middle-of-the-Night Awakening as Measured by Polysomnography for a Subpopulation of Participants With More Severe Insomnia","description":"Polysomnography was used to measure the time to return to persistent sleep after a middle-of-the-night (MOTN) awakening for each day of every two-day treatment period in a subpopulation of patients with greater than 60 minutes to fall asleep after a MOTN awakening at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.62","spread":null},{"groupId":"OG001","value":"23.28","spread":null},{"groupId":"OG002","value":"37.89","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjective Sleep Quality Rating","description":"Sleep quality was rated by participants for each day of every two-day treatment period using the Treatment Morning Sleep Questionnaire. The percentage of participants within each rating category is reported. The rating scale was poor, fair, good and excellent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"29.3","spread":null},{"groupId":"OG002","value":"34.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.8","spread":null},{"groupId":"OG001","value":"37.8","spread":null},{"groupId":"OG002","value":"42.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.3","spread":null},{"groupId":"OG001","value":"30.5","spread":null},{"groupId":"OG002","value":"19.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"2.4","spread":null},{"groupId":"OG002","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjective Level of Refreshed Sleep","description":"Level of refreshed sleep was rated by participants for each day of every two-day treatment period using the Treatment Morning Sleep Questionnaire. The percentage of participants within each rating category is reported. The rating scale was poor, fair, good and excellent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"22.0","spread":null},{"groupId":"OG002","value":"32.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.5","spread":null},{"groupId":"OG001","value":"41.5","spread":null},{"groupId":"OG002","value":"44.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":null},{"groupId":"OG001","value":"34.1","spread":null},{"groupId":"OG002","value":"19.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"2.4","spread":null},{"groupId":"OG002","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjective Ability to Function","description":"Ability to function was rated by participants for each day of every two-day treatment period using the Treatment Morning Sleep Questionnaire. The percentage of participants within each rating category is reported. The rating scale was poor, fair, good and excellent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"9.8","spread":null},{"groupId":"OG002","value":"18.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":null},{"groupId":"OG001","value":"42.7","spread":null},{"groupId":"OG002","value":"42.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","spread":null},{"groupId":"OG001","value":"41.5","spread":null},{"groupId":"OG002","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"6.1","spread":null},{"groupId":"OG002","value":"6.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Polysomnography Sleep Efficiency After Scheduled Middle-of-the-Night Awakening","description":"Sleep efficiency is a measurement of the percentage of time asleep to the total time in bed. It was measured by polysomnography for each day of every two-day treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.08","spread":null},{"groupId":"OG001","value":"82.63","spread":null},{"groupId":"OG002","value":"76.31","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjective Sleep Onset Latency After Middle-of-the-Night Awakening","description":"Participants documented the time to return to sleep after a middle-of-the-night (MOTN) awakening for each day of every two-day treatment period using the Treatment Morning Sleep Questionnaire.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.23","spread":null},{"groupId":"OG001","value":"28.58","spread":null},{"groupId":"OG002","value":"40.43","spread":null}]}]}]},{"type":"SECONDARY","title":"Polysomnography Wake Time After Sleep Onset Following Middle-of-the-Night Awakening","description":"Amount of time awake after sleep onset following a middle-of-the-night awakening was measured by polysomnography for each day of every two-day treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.06","spread":null},{"groupId":"OG001","value":"15.81","spread":null},{"groupId":"OG002","value":"15.71","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjective Wake Time After Sleep Onset After Middle-of-the-Night Awakening","description":"Amount of time awake after sleep onset following a middle-of-the-night awakening was recorded by participants using the Treatment Morning Sleep Questionnaire for each day of every two-day treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.69","spread":null},{"groupId":"OG001","value":"29.43","spread":null},{"groupId":"OG002","value":"34.22","spread":null}]}]}]},{"type":"SECONDARY","title":"Polysomnography Number of Awakenings After Middle-of-the-Night Awakening","description":"Number of times a participant awoke following sleep onset after the middle-of-the-night awakening, as measured by polysomnography for each day of every two-day treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.71","spread":null},{"groupId":"OG001","value":"3.70","spread":null},{"groupId":"OG002","value":"4.13","spread":null}]}]}]},{"type":"POST_HOC","title":"Subjective Number of Awakenings After Middle-of-the-Night Awakening","description":"Number of times a participant awoke following sleep onset after the middle-of-the-night awakening, as documented by the participant for each day of every two-day treatment period using the Treatment Morning Sleep Questionnaire.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":null},{"groupId":"OG001","value":"1.03","spread":null},{"groupId":"OG002","value":"1.14","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":80},"commonTop":[]}}}